Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q3 2024 Earnings Presentation
11 slides from Adc Therapeutics Sa's earnings presentation, Nov 7, 2024
Slide 1: 3Q 2024 Earnings Call
3Q 2024 Earnings Call November 7, 2024
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Business Update Pepe Carmona Financial Update 02 Chief Financial Officer 03 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Key Business Updates
Key Business Updates Commercial ▪ 3Q 2024 net product revenues of $18.0 million as compared to $14.3 million in same quarter 2023 Performance ▪ 2024 ZYNLONTA® revenues of $52.9 million YTD as compared to $52.4 million for same period in 2023 ▪ LOTIS-5 enrollment nearing completion with full enrollme
Slide 5: Significant Opportunity for ZYNLONTA Combinations in Evolving r/r DLBCL Market
Significant Opportunity for ZYNLONTA Combinations in Evolving r/r DLBCL Market 2L+ Market Dynamics* Projected Trend1 Efficacy Safety Accessibility Share Cell Therapy ZYNLONTA LOTIS 7 Bispecifics Potential for highly competitive efficacy with better safety and accessibility ZYNLONTA LOTIS 5 ADCs / mA
Slide 6: Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas
Advancing ZYNLONTA Development into 2L+ B-Cell Lymphomas DLBC F MZ POTENTIAL TO MOVE INTO 2L+ DLBCL L L L → LOTIS-5 (ZYNLONTA + rituximab): 20 patient safety run-in data showed ORR of 80%, CR of 50% with no new safety signals 1 → LOTIS-7 (ZYNLONTA + bispecific): Dose L escalation in Phase 1b trial c
Slide 7: 3Q 2024 Selected Financial Data
3Q 2024 Selected Financial Data Balance Sheet September 30, 2024 Cash and cash equivalents ($M) 274.3 GAAP Non-GAAP (Adjusted)* Statement of Operations 3Q 2024 ($M) % vs. 3Q 2023 3Q 2024 ($M) % vs. 3Q 2023 Product Revenues, Net 18.0 26.3 18.0 26.3 Research & Development 32.5 20.0 31.5 17.0 Expenses
Slide 8: Corporate Business Development Strategy for ADCT Portfolio
Corporate Business Development Strategy for ADCT Portfolio U.S. EX-U.S. HEMATOLOGY OVERLAND JOINT VENTURE DIREC PARTNERSHI T P Business Development Opportunities to Unlock Value SOLID TUMORS Royalty & Co-development & Milestones to Co-promote* ADCT Business Development Goals: 1 2 3 Maximize Deal Non
Slide 9: Delivering On Our Strategy
Delivering On Our Strategy 2024 Milestones Achieved Upcoming Expected Milestones q Achieved commercial brand profitability q ZYNLONTA 3Q 2024 YTD q LOTIS-7: Initial efficacy/safety update on Part 2 with glofitamab in December 2024; additional data in 1H q LOTIS-7: Completed dose escalation with 2025
Slide 10: Thank You
Thank You ® THERAPEUTICS Innovating Science. Inspiring Hope.
Slide 11: Reconciliation of GAAP Measures to Non-GAAP Measures
Reconciliation of GAAP Measures to Non-GAAP Measures Unaudited (in thousands) in $'000 3Q 2024 3Q 2023 Net loss (GAAP) $ (43,969) $ (46,726) Adjustments: Share-based compensation expense - R&D (i) 991 157 Share-based compensation expense - S&M (i) 355 162 Share-based compensation expense - G&A (i) 1